Allopurinol and Pathogenesis of Cirrhosis

Hepatic decompensation is a common healthcare issue

. This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cirrhoses, Liver

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Tanta University

Tanta, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age 18-75 both sex

Exclusion criteria

active GIT bleeding

Treatment and study plan

Allopurinol Tablet

Drug

allopurinol 300

Placebo

Drug

placebo tablet

Primary outcomes

biomarkers as zonulin, LPS, MMP-13, MDA

Time frame: 6 MONTHS

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Allopurinol Interferes With the Pathological Mechanisms of Hepatic Decompensation

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Jun 24, 2025
Registry last updated: Jun 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed